ReviewOral oncology2023
Patient-derived three-dimensional culture techniques model tumor heterogeneity in head and neck cancer.
Review in Oral oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 11 citations in OpenAlex.
- A Head and Neck Cancer Patient-Specific Microphysiological System for Predicting Response to Chemoradiation.bioRxiv : the preprint server for biology · 2026Article
- Article
- Application of Digital Medicine to the Diagnosis and Treatment of Head and Neck Tumors.Cancer reports (Hoboken, N.J.) · 2026Review
- Head and neck cancer organoids: a panoramic perspective from basic construction to clinical translation.Stem cell research & therapy · 2025Review
- Head and neck tumor organoid grown under simplified media conditions model tumor biology and chemoradiation responses.Scientific reports · 2025Article
- Organoid Technology in Precision Medicine for Head and Neck Cancer.Oncology research · 2025Review
- Article
- Retinol-binding protein type 1 expression predicts poor prognosis in head and neck squamous cell carcinoma.BMC cancer · 2024Article
- Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review).Oncology reports · 2024Review
- Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.Biomedicines · 2024Article
- ALDH2 dysfunction and alcohol cooperate in cancer stem cell enrichment.Carcinogenesis · 2024Article
- Correlation between clinicopathological indices and expression of cluster of differentiation 24 and cluster of differentiation 44 biomarkers in oral epithelial dysplasia and oral squamous cell carcinoma patients: A follow-up study.Dental research journal · 2024Article
- Neoantigen cancer vaccines: a new star on the horizon.Cancer biology & medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) outcomes remain stagnant, in part due to a poor understanding of HNSCC biology. The importance of tumor heterogeneity as an independent predictor of outcomes and treatment failure in HNSCC has recently come to light. With this understanding, 3D culture systems, including patient derived organoids (PDO) and organotypic culture (OTC), that capture this heterogeneity may allow for modeling and manipulation of critical subpopulations, such as p-EMT, as well as interactions between cancer cells and immune and stromal cells in the microenvironment. Here, we review work that has been done using PDO and OTC models of HNSCC, which demonstrates that these 3D culture models capture in vivo tumor heterogeneity and can be used to model tumor biology and treatment response in a way that faithfully recapitulates in vivo characteristics. As such, in vitro 3D culture models represent an important bridge between 2D monolayer culture and in vivo models such as patient derived xenografts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.